In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung function and asthma control in patients with moderate to severe type 2 asthma.

Baseline factors that positively impacted clinical remission odds on dupilumab ... no asthma exacerbations (attacks), no symptoms, no oral corticosteroid (OCS) and stable or improved lung function ...

Roshni Naik, MD, allergist at Mount Sinai Health System, discusses the results after treating a case of severe asthma with nasal polyps: "After five months of starting Dupilumab frequency of ...

A highly effective drug for a debilitating lung disease is set to become the first new treatment for the condition in more than a decade. The medicine – dupilumab – has been shown to ...